JP2016512551A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512551A5
JP2016512551A5 JP2016501731A JP2016501731A JP2016512551A5 JP 2016512551 A5 JP2016512551 A5 JP 2016512551A5 JP 2016501731 A JP2016501731 A JP 2016501731A JP 2016501731 A JP2016501731 A JP 2016501731A JP 2016512551 A5 JP2016512551 A5 JP 2016512551A5
Authority
JP
Japan
Prior art keywords
seq
antibody
cdr
heavy chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016501731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512551A (ja
JP6674888B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/025044 external-priority patent/WO2014165271A2/en
Publication of JP2016512551A publication Critical patent/JP2016512551A/ja
Publication of JP2016512551A5 publication Critical patent/JP2016512551A5/ja
Application granted granted Critical
Publication of JP6674888B2 publication Critical patent/JP6674888B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016501731A 2013-03-13 2014-03-12 タウ免疫療法 Active JP6674888B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361780624P 2013-03-13 2013-03-13
US61/780,624 2013-03-13
US201361800382P 2013-03-15 2013-03-15
US61/800,382 2013-03-15
PCT/US2014/025044 WO2014165271A2 (en) 2013-03-13 2014-03-12 Tau immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020039557A Division JP7044399B2 (ja) 2013-03-13 2020-03-09 タウ免疫療法

Publications (3)

Publication Number Publication Date
JP2016512551A JP2016512551A (ja) 2016-04-28
JP2016512551A5 true JP2016512551A5 (enExample) 2017-04-06
JP6674888B2 JP6674888B2 (ja) 2020-04-01

Family

ID=51659327

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016501731A Active JP6674888B2 (ja) 2013-03-13 2014-03-12 タウ免疫療法
JP2020039557A Active JP7044399B2 (ja) 2013-03-13 2020-03-09 タウ免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020039557A Active JP7044399B2 (ja) 2013-03-13 2020-03-09 タウ免疫療法

Country Status (19)

Country Link
US (3) US10501531B2 (enExample)
EP (2) EP2970453B1 (enExample)
JP (2) JP6674888B2 (enExample)
KR (1) KR102313513B1 (enExample)
CN (1) CN105121465B (enExample)
AU (2) AU2014248515B2 (enExample)
BR (1) BR112015022260B1 (enExample)
CA (1) CA2902026C (enExample)
CU (1) CU24446B1 (enExample)
EA (1) EA035943B1 (enExample)
ES (1) ES2766762T3 (enExample)
IL (1) IL241124B (enExample)
MX (2) MX375354B (enExample)
PE (1) PE20152004A1 (enExample)
PH (1) PH12015501926A1 (enExample)
SA (1) SA515361031B1 (enExample)
SG (2) SG11201506244VA (enExample)
WO (1) WO2014165271A2 (enExample)
ZA (1) ZA201507464B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6345655B2 (ja) 2012-07-03 2018-06-20 ワシントン・ユニバーシティWashington University タウに対する抗体
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
KR101791296B1 (ko) * 2014-04-17 2017-10-27 제주대학교 산학협력단 알츠하이머병 관련 돌연변이 유전자를 포함하는 발현 카세트, 벡터, 및 이를 이용하여 형질전환된 세포주
TW202136296A (zh) 2014-06-27 2021-10-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
EP3261670A4 (en) 2015-02-24 2018-08-01 Rpeptide, LLC Anti-tau antibodies
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
MA41842A (fr) 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
MX2017015908A (es) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CA3022673A1 (en) * 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
EA201892412A1 (ru) * 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
PH12019500056B1 (en) 2016-07-12 2024-01-31 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
KR102551971B1 (ko) 2016-07-12 2023-07-07 하. 룬드벡 아크티에셀스카브 과인산화된 타우에 특이적인 항체 및 이의 사용 방법
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
EP3496750A2 (en) 2016-08-09 2019-06-19 Eli Lilly and Company Combination therapy
GB201614884D0 (en) * 2016-09-01 2016-10-19 Oblique Therapeutics Ab Method
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
AR110321A1 (es) 2016-12-07 2019-03-20 Genentech Inc Anticuerpos antitau y métodos de uso
CN110267985B (zh) 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
BR112019015075A2 (pt) 2017-01-23 2020-03-10 Revolution Medicines, Inc. Compostos bicíclicos como inibidores de shp2 alostéricos
SG11201906412SA (en) 2017-01-23 2019-08-27 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
MX2019011423A (es) 2017-03-28 2019-11-01 Genentech Inc Metodos de tratamiento de enfermedades neurodegenerativas.
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
JP7356414B2 (ja) 2017-09-07 2023-10-04 レヴォリューション・メディスンズ,インコーポレイテッド がんを治療するためのshp2阻害剤組成物および方法
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
NZ762251A (en) 2017-10-16 2025-12-19 Eisai R&D Man Co Ltd Anti-tau antibodies and uses thereof
EA202091012A1 (ru) 2017-10-25 2020-08-27 Янссен Фармасьютикалз, Инк. Композиции фосфорилированных тау-пептидов и их применения
CA3084058A1 (en) 2017-12-15 2019-06-20 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
WO2019207159A1 (en) * 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
CN112543648A (zh) 2018-07-31 2021-03-23 伊莱利利公司 组合疗法
CN113710269A (zh) 2019-02-08 2021-11-26 Ac免疫有限公司 磷酸化Tau肽疫苗的安全施用方法
CN113597431B (zh) * 2019-02-08 2025-02-21 普罗塞纳生物科学有限公司 识别Tau的抗体
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
JP7181438B2 (ja) 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
JP2023526500A (ja) 2020-05-19 2023-06-21 オター プロシーナ リミテッド アルツハイマー病の処置のためのマルチエピトープワクチン
EP4192497A4 (en) 2020-08-07 2024-08-21 Othair Prothena Limited MULTI-EPITOPIC VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
CN113254929B (zh) * 2021-05-21 2023-11-07 昆山翦统智能科技有限公司 一种企业远程智能服务的免疫计算与决策方法及系统
MX2024002295A (es) 2021-08-27 2024-03-07 Genentech Inc Metodos para tratar las patologias de tau.
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023178049A1 (en) 2022-03-14 2023-09-21 Genentech, Inc. Predicting neurodegenerative diseases based on speech analyses
WO2023250326A1 (en) 2022-06-21 2023-12-28 Genentech, Inc. Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses
CN120019071A (zh) 2022-09-15 2025-05-16 沃雅戈治疗公司 Tau结合化合物
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
DK0673418T3 (da) 1992-12-14 1999-03-01 Innogenetics Nv Monoklonale antistoffer rettet mod mikrotubulusassocieret tau-protein, hybridomaer, der secernerer disse antistoffer, antig
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン,インコーポレイティド 万能dr−結合性ペプチドを用いる免疫応答の改変
US5877218A (en) 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
DE60045319D1 (de) 1999-02-05 2011-01-13 Samsung Electronics Co Ltd Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
ES2352668T3 (es) 2002-08-14 2011-02-22 Mitsubishi Chemical Medience Corporation Anticuerpo específico para una proteína tau del sistema nervioso central.
ES2293096T3 (es) 2002-11-29 2008-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
US7847146B2 (en) * 2003-03-28 2010-12-07 Baylor College Of Medicine Model for neurodegenerative disorders
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US20050132424A1 (en) * 2003-10-21 2005-06-16 Envivo Pharmaceuticals, Inc. Transgenic flies expressing Abeta42-Dutch
JP2008520186A (ja) * 2004-10-01 2008-06-19 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 哺乳類eag1イオンチャネルタンパク質に対する新規の抗体
PL1820022T3 (pl) 2004-11-10 2009-11-30 Boehringer Ingelheim Pharma Zastosowanie analizy metodą cytometrii przepływowej w optymalizacji strategii dla banków komórek jajnika chińskiego chomika
CA2591665C (en) * 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
WO2006074071A1 (en) 2004-12-30 2006-07-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Framework residue substituted humanized col-1 antibodies and their use
AU2006287416A1 (en) * 2005-09-07 2007-03-15 Medimmune, Llc Toxin conjugated Eph receptor antibodies
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
CA2655634A1 (en) * 2006-06-16 2007-12-27 Envivo Pharmaceuticals, Inc. Transgenic flies expressing tau and amyloid precursor fragment
WO2007147213A1 (en) * 2006-06-22 2007-12-27 Walter And Eliza Hall Institute Of Medical Research Structure of the insulin receptor ectodomain
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US20100216703A1 (en) * 2006-08-14 2010-08-26 The Regents Of The University Of California Inhibitors of PDE4 and Methods of Use
EP2097097B1 (en) 2006-12-01 2018-05-30 E. R. Squibb & Sons, L.L.C. Antibodies, in particular human antibodies, that bind cd22 and uses thereof
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
JP5467415B2 (ja) 2007-03-02 2014-04-09 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト タンパク質製造の改良
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP2009056790A (ja) 2007-09-03 2009-03-19 Takao Otogawa ファイル用ポケット
AU2008303796B2 (en) 2007-09-26 2014-09-18 Amgen Inc. Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
US9272030B2 (en) 2007-10-17 2016-03-01 Janssen Sciences Ireland Uc Use of tau to monitor immunotherapy
MX2010005282A (es) * 2007-11-13 2010-08-31 Teva Pharma Anticuerpos humanizados contra tl1a.
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
JP2010014691A (ja) 2008-06-20 2010-01-21 Igaku Seibutsugaku Kenkyusho:Kk 腹水中のメソテリン及び/又は巨核球増強因子を検出するための方法、キット、試薬及び装置
KR101772706B1 (ko) 2008-08-18 2017-08-29 화이자 인크. Ccr2에 대한 항체
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
CA3239368A1 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
US20110045534A1 (en) 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
WO2011053565A2 (en) 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
WO2011075636A2 (en) * 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
JP5697044B2 (ja) 2010-01-08 2015-04-08 国立大学法人京都大学 タウオパチー治療用ワクチン
NZ601293A (en) 2010-02-23 2014-10-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
ITRM20100320A1 (it) * 2010-06-11 2011-12-11 Consiglio Nazionale Ricerche Metodo per la diagnostica e il trattamento delle taupatie
US20120023911A1 (en) 2010-07-28 2012-02-02 Gm Global Technology Operations, Inc. Detection of exhaust particulate filter substrate failure
SG189174A1 (en) 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
EP2673635A4 (en) 2011-02-07 2015-08-12 Neotope Biosciences Ltd IMMUNOTHERAPY THROUGH APOE
WO2012149365A2 (en) 2011-04-27 2012-11-01 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
US9518101B2 (en) 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
ES2600915T3 (es) 2011-10-07 2017-02-13 Ac Immune S.A. Anticuerpos fosfoespecíficos que reconocen Tau
AR090352A1 (es) 2012-03-28 2014-11-05 Sanofi Sa Anticuerpos frente a los ligandos del receptor b1 de bradicinina
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
US9428864B2 (en) 2012-04-18 2016-08-30 E I Du Pont De Nemours And Company Multilayered sheet
DE102012211455A1 (de) 2012-07-02 2014-01-02 Wobben Properties Gmbh Handhabungsvorrichtung zum Handhaben einer Rotorblattform zum Fertigen eines Rotorblattes einer Windenergieanlage
JP6345655B2 (ja) * 2012-07-03 2018-06-20 ワシントン・ユニバーシティWashington University タウに対する抗体
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
EP4356927A3 (en) 2012-10-12 2024-10-02 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
HRP20201422T1 (hr) 2012-12-21 2021-02-19 Biogen Ma Inc. Ljudska anti-tau antitijela
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US9364191B2 (en) 2013-02-11 2016-06-14 University Of Rochester Method and apparatus of spectral differential phase-contrast cone-beam CT and hybrid cone-beam CT
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
CA2903091C (en) 2013-03-15 2022-09-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
EP3418430B1 (en) 2013-03-15 2023-03-29 The Trustees of the University of Pennsylvania Blood biomarkers that predict persistent cognitive dysfunction after concussion
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
CN111569063A (zh) 2013-11-27 2020-08-25 伊皮埃里安股份有限公司 治疗tau病变的方法
CN106030310B (zh) 2013-12-13 2019-01-04 通用医疗公司 可溶性高分子量(hmw)tau种类及其应用
MX379030B (es) * 2013-12-17 2025-03-10 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
US9629801B2 (en) 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
US20150253341A1 (en) 2014-02-10 2015-09-10 Merck Sharp & Dohme Corp. Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
NZ727020A (en) 2014-06-26 2022-02-25 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW202136296A (zh) 2014-06-27 2021-10-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
HRP20210124T1 (hr) 2014-11-19 2021-03-19 Axon Neuroscience Se Humanizirana tau antitijela u alzheimerovoj bolesti
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3261670A4 (en) 2015-02-24 2018-08-01 Rpeptide, LLC Anti-tau antibodies
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
WO2016201434A2 (en) 2015-06-12 2016-12-15 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
MX2017015908A (es) 2015-07-06 2018-03-15 Ucb Biopharma Sprl Anticuerpos de union a tau.
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
CN107849125A (zh) 2015-07-21 2018-03-27 生命北极神经科学公司 用于治疗靶向聚集的肽的创伤性脑损伤的方法
EP3359569A2 (en) 2015-10-06 2018-08-15 Alector LLC Anti-trem2 antibodies and methods of use thereof
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
EA201892412A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
US10947302B2 (en) 2016-11-04 2021-03-16 The Regents Of The University Of California Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
AR110321A1 (es) 2016-12-07 2019-03-20 Genentech Inc Anticuerpos antitau y métodos de uso
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
WO2018156250A1 (en) 2017-02-21 2018-08-30 Remd Biotherapeutics, Inc. Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
TWI771389B (zh) 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
KR20190133191A (ko) 2017-03-28 2019-12-02 얀센 백신스 앤드 프리벤션 비.브이. 타우에 특이적으로 결합하는 결합 분자
MX2019011423A (es) 2017-03-28 2019-11-01 Genentech Inc Metodos de tratamiento de enfermedades neurodegenerativas.
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN110770253A (zh) 2017-06-16 2020-02-07 百时美施贵宝公司 用于治疗tau蛋白病的组合物和方法
NZ762251A (en) 2017-10-16 2025-12-19 Eisai R&D Man Co Ltd Anti-tau antibodies and uses thereof
US11591385B2 (en) 2017-11-09 2023-02-28 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2019110571A1 (en) 2017-12-04 2019-06-13 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
TW202003036A (zh) 2018-03-23 2020-01-16 德商艾伯維德國有限及兩合公司 穩定水性抗-tau抗體調配物
WO2019186276A2 (en) 2018-03-28 2019-10-03 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
WO2019207159A1 (en) 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
CA3118818A1 (en) 2018-11-08 2020-05-14 Prothena Biosciences Limited Antibodies recognizing tau
EP3877410A4 (en) 2018-11-08 2022-08-10 Prothena Biosciences Limited ANTIBODIES RECOGNIZING TAU PROTEIN
CN113490505A (zh) 2018-11-19 2021-10-08 德克萨斯大学系统董事会 用于治疗tau蛋白病的tau肽抗原及与其结合的抗体
CN113597431B (zh) 2019-02-08 2025-02-21 普罗塞纳生物科学有限公司 识别Tau的抗体
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
EP3947446A1 (en) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
GB2600599B (en) 2019-07-15 2025-05-21 Adel Inc Anti-Tau antibody and use thereof

Similar Documents

Publication Publication Date Title
JP2012530496A5 (enExample)
JP2017052784A5 (enExample)
JP2018183173A5 (enExample)
JP2013545455A5 (enExample)
JP2011514150A5 (enExample)
JP2017526370A5 (enExample)
JP2014534242A5 (enExample)
JP2015504306A5 (enExample)
JP2010022372A5 (enExample)
JP2021514973A5 (enExample)
IL262726B1 (en) Antibodies recognizing tau
RU2016100892A (ru) Антитела против tweakr и их применение
JP2020511947A5 (enExample)
JP2018510636A5 (enExample)
JP2016511277A5 (enExample)
JP2019525724A5 (enExample)
JP2015533853A5 (enExample)
JP2018510617A5 (enExample)
JP2016505546A5 (enExample)
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2015533795A5 (enExample)
JP2010526028A5 (enExample)
JP2011046732A5 (enExample)
RU2017119185A (ru) Антитела против fgfr2/3 и способы их применения
PE20091474A1 (es) Anticuerpos monoclonales contra la proteina rgm a y sus usos